CMAB Biopharma and Fapon Biopharma Sign Agreement to Develop and Manufacture a Biologic Oncology Asset

Publisher: The Insight Partners

CMAB Biopharma (Suzhou) Inc. ("CMAB"), a pure-play, biologics contract manufacturing and development organization (CDMO) and Shenzhen Fapon Biopharma Inc. ("Fapon Biopharma"), an innovative biopharmaceutical company, announced a comprehensive strategic agreement for the development and manufacturing of an undisclosed biologic drug project.

According to the agreement, Fapon Biopharma will avail of the fully integrated CMC process development and manufacturing platform, the European QP audited product quality system and the experienced regulatory team in dual IND filings in both China and the United States at CMAB.

Quote from Dr. Lisheng Lu, Chief Scientist of Fapon Biopharma:

"Fapon Biotechnology is a leading supplier of raw materials and solutions for IVD reagent, which is well-known in the industry for its leading R&D technology and excellent product quality.

With in-depth understanding of the pharmaceutical industry and strong resource support, Fapon Biopharma was established in 2015. With innovation-driven R&D as the core, our positioning is to develop and produce high-quality innovative biopharmaceuticals to save patients' lives.

After communication and the on-site investigation, we found that Fapon Biopharma is highly consistent with CMAB. Meeting our core needs, CMAB has a deep understanding of biologic drugs, and can formulate a CMC strategy to help us control risks and ensure that the milestones of each stage can be quickly reached with high quality."

Quote from Dr. Yongzhong Wang, CEO of CMAB Biopharma:

"We are very excited and proud to be able to closely participate in this meaningful biologic drug development project of Fapon Biopharma. The founding aspiration and goal of CMAB is to make our customers successful as quickly as possible. We are willing and confident to work with innovative biopharmaceutical companies such as Fapon Biopharma to overcome technical difficulties, reduce R&D costs, reach milestones quickly and of high quality, and create sustainable value for customers."